Advancing Chronic Wound Healing through Immune Modulation: Insights from Biomaterials and Nanomedicine

Evelyn Chang^*
*Correspondence: Evelyn Chang, Department of Dermatology, Freie Universität Berlin, 14195 Berlin, Germany, Email:

Keywords

Chronic wound • Immune modulation • Wound healing

Introduction

Chronic wounds, including diabetic ulcers, venous ulcers, and pressure ulcers, pose significant healthcare burdens worldwide due to their persistent nature and limited treatment options. These wounds are characterized by prolonged inflammation, impaired tissue regeneration, and susceptibility to recurrent infections, leading to substantial morbidity and healthcare costs. Conventional wound care strategies often focus on infection control, debridement, and the application of wound dressings to promote healing. However, these approaches do not address the underlying immune dysregulation that contributes to chronic wound pathophysiology. Recent insights into wound healing mechanisms have underscored the pivotal role of immune responses in orchestrating tissue repair processes. The immune system's ability to balance pro-inflammatory and anti-inflammatory signals is crucial for initiating and resolving inflammation, promoting tissue remodeling, and facilitating wound closure.

Dysregulated immune responses, such as persistent inflammation or impaired immune cell recruitment, contribute to the chronicity of wounds and hinder healing progress. Therefore, strategies aimed at modulating immune responses represent promising avenues for enhancing chronic wound healing outcomes. Biomaterials and nanomedicine have emerged as innovative platforms for immune modulation in wound healing applications. These technologies enable precise control over immune cell interactions, cytokine signaling, and tissue regeneration processes within the wound microenvironment. Biomaterials such as hydrogels, scaffolds, and nanoparticles can be engineered to deliver bioactive molecules, modulate immune cell behavior, and provide structural support to facilitate tissue repair. Nanomedicine approaches leverage nanoscale materials for targeted delivery of therapeutic agents, enhancing efficacy while minimizing systemic side effects [1].

Literature Review

Recent advances in biomaterials and nanomedicine have demonstrated their potential to modulate immune responses and promote functional wound healing in chronic wound models. Biomaterial-based approaches offer versatility in designing scaffolds and dressings that mimic the Extracellular Matrix (ECM) and provide a supportive environment for cell adhesion, migration, and proliferation. For instance, hydrogel scaffolds incorporating growth factors or immunomodulatory agents have shown promise in enhancing wound closure rates and promoting angiogenesis by regulating inflammatory cytokine release and immune cell recruitment. Nanoparticle-based systems provide targeted delivery of bioactive molecules, such as growth factors, antiinflammatory drugs, or antimicrobial agents, directly to the wound site. These nanoparticles can penetrate the wound bed, release therapeutic payloads in a controlled manner, and modulate immune cell responses to promote tissue repair. Moreover, nanocarriers engineered with surface modifications or stimuli-responsive properties enable spatiotemporal control over drug release kinetics, optimizing therapeutic efficacy and minimizing off-target effects.

In addition to delivering therapeutic agents, biomaterials and nanomedicine platforms facilitate immunomodulation by influencing immune cell phenotype and function. Encapsulation of immunomodulatory factors within biomaterial scaffolds can polarize macrophages towards anti-inflammatory M2 phenotypes, which promote tissue regeneration and resolution of inflammation. Similarly, nanoparticles functionalized with targeting ligands can selectively deliver immune-modulating drugs to specific immune cell subsets within the wound microenvironment, modulating cytokine production and enhancing wound healing outcomes [2,3]. Clinical translation of these technologies has demonstrated encouraging results in improving chronic wound management. Clinical trials evaluating biomaterial-based dressings and nanomedicine formulations have reported accelerated wound closure rates, reduced infection rates, and improved patient quality of life compared to conventional therapies. Moreover, these approaches offer potential costeffectiveness by reducing hospitalization duration and healthcare utilization associated with chronic wound care [4].

Discussion

The integration of biomaterials and nanomedicine in immune modulation for chronic wound healing represents a paradigm shift in wound care strategies. By targeting immune dysregulation at the cellular and molecular levels, these technologies address critical barriers to effective wound healing and offer personalized therapeutic approaches tailored to patientspecific wound characteristics. Biomaterials provide a versatile platform for delivering bioactive molecules and modulating immune cell behavior within the wound microenvironment, whereas nanomedicine enables precise and targeted delivery of therapeutics to enhance efficacy and minimize systemic side effects. The multifunctional properties of biomaterials and nanoparticles also facilitate combinatorial approaches that synergistically enhance wound healing outcomes. For example, hybrid biomaterial scaffolds incorporating both growth factors and antimicrobial agents can promote tissue regeneration while preventing infection, addressing two key challenges in chronic wound management simultaneously.

Furthermore, the development of smart biomaterials with responsive properties, such as pH-sensitive or temperature-sensitive hydrogels, enables dynamic modulation of drug release kinetics in response to changes in the wound environment, optimizing therapeutic efficacy over time. Challenges in translating these technologies from bench to bedside include regulatory considerations, scalability of manufacturing processes, and costeffectiveness compared to conventional wound care therapies. Regulatory agencies require robust preclinical and clinical data demonstrating safety, efficacy, and reproducibility of biomaterials and nanomedicine formulations for wound healing applications. Standardization of manufacturing protocols and quality control measures is essential to ensure consistency and reliability of therapeutic outcomes across different patient populations and healthcare settings [5].

Moreover, interdisciplinary collaborations between scientists, clinicians, and industry partners are crucial for advancing biomaterials and nanomedicine technologies in wound healing. By fostering collaborations, researchers can leverage expertise in materials science, immunology, pharmacology, and clinical medicine to innovate new therapeutic strategies and accelerate translation from benchtop discoveries to clinical implementation. Long-term studies evaluating the durability of immune-modulating effects and patient outcomes following biomaterial-based interventions will further elucidate the potential benefits and limitations of these technologies in chronic wound management [6].

Conclusion

In conclusion, biomaterials and nanomedicine represent transformative tools for advancing chronic wound healing through immune modulation. By harnessing the innate capabilities of the immune system, these technologies offer innovative approaches to address the complexities of chronic wound pathophysiology, including persistent inflammation, impaired tissue regeneration, and susceptibility to infection. Biomaterials provide a customizable platform for delivering bioactive molecules and modulating immune cell responses within the wound microenvironment, promoting tissue repair and resolution of inflammation. Nanomedicine approaches enhance therapeutic efficacy by enabling targeted delivery of drugs and growth factors directly to the wound site, optimizing local concentrations while minimizing systemic side effects. Clinical studies have demonstrated promising outcomes, including accelerated wound closure rates and improved patient quality of life, supporting the potential of these technologies to revolutionize chronic wound care. Moving forward, continued research efforts and collaborative partnerships are essential to overcome translational challenges, refine therapeutic strategies, and establish biomaterials and nanomedicine as standard-of-care treatments for chronic wounds globally.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Las Heras, Kevin, Manoli Igartua, Edorta Santos-Vizcaino and Rosa Maria Hernandez. "Chronic wounds: Current status, available strategies and emerging therapeutic solutions." JCR 328 (2020): 532-550.

   Google Scholar, Crossref, Indexed at

2. Powers, Jennifer G., Catherine Higham, Karen Broussard and Tania J. Phillips. "Wound healing and treating wounds: Chronic wound care and management." JAAD 74 (2016): 607-625.

   Google Scholar, Crossref, Indexed at

3. Elkhalifa, Ahmed ME, Sofi Imtiyaz Ali, Showkat Ul Nabi and Imran Bashir, et al. "Modulation of immune cum inflammatory pathway by earthworm granulation tissue extract in wound healing of diabetic rabbit model." Heliyon 10(2024).

   Google Scholar, Crossref, Indexed at

4. Yang, Jiaying, Mengyu Lai, Yuhang Ma and Jingzhu Wu, et al. "Spatiotemporal modulation of immune microenvironment via composite hydrogel brakes for diabetic wound healing." J Chem Eng 493 (2024): 152251.

   Google Scholar, Crossref, Indexed at

5. Cardoso, Cristina Ribeiro, S. Favoreto Jr, Leandro Licursi de Oliveira and Jaqueline Oliveira Vancim, et al. "Oleic acid modulation of the immune response in wound healing: A new approach for skin repair." Immunobiology 216 (2011): 409-415.

   Google Scholar, Crossref, Indexed at

6. Dyson, M. "5 modulation of wound healing by the systemic effects of light on the immune system." PDPDT 5 (2008): S2.

   Google Scholar, Crossref